TWI348916B - A novel treatment tool for cancer: rna interference of bcas2 - Google Patents

A novel treatment tool for cancer: rna interference of bcas2

Info

Publication number
TWI348916B
TWI348916B TW097112076A TW97112076A TWI348916B TW I348916 B TWI348916 B TW I348916B TW 097112076 A TW097112076 A TW 097112076A TW 97112076 A TW97112076 A TW 97112076A TW I348916 B TWI348916 B TW I348916B
Authority
TW
Taiwan
Prior art keywords
bcas2
cancer
treatment tool
rna interference
novel treatment
Prior art date
Application number
TW097112076A
Other languages
English (en)
Other versions
TW200942264A (en
Inventor
Show Li Chen
Shinn Tsuen Lin
Hung Wei Chang
Original Assignee
Univ Nat Taiwan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nat Taiwan filed Critical Univ Nat Taiwan
Publication of TW200942264A publication Critical patent/TW200942264A/zh
Application granted granted Critical
Publication of TWI348916B publication Critical patent/TWI348916B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/111Antisense spanning the whole gene, or a large part of it
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW097112076A 2008-04-03 2008-04-02 A novel treatment tool for cancer: rna interference of bcas2 TWI348916B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/062,478 US7718631B2 (en) 2008-04-03 2008-04-03 Treatment tool for cancer: RNA interference of BCAS2

Publications (2)

Publication Number Publication Date
TW200942264A TW200942264A (en) 2009-10-16
TWI348916B true TWI348916B (en) 2011-09-21

Family

ID=39742257

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097112076A TWI348916B (en) 2008-04-03 2008-04-02 A novel treatment tool for cancer: rna interference of bcas2

Country Status (2)

Country Link
US (1) US7718631B2 (zh)
TW (1) TWI348916B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110387424A (zh) * 2019-07-12 2019-10-29 安徽农业大学 Bcas2基因用于判断圩公猪初情期启动时间的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044321A2 (en) * 2000-12-01 2002-06-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference mediating small rna molecules
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
US20070009899A1 (en) * 2003-10-02 2007-01-11 Mounts William M Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases

Also Published As

Publication number Publication date
US7718631B2 (en) 2010-05-18
TW200942264A (en) 2009-10-16
US20080221059A1 (en) 2008-09-11

Similar Documents

Publication Publication Date Title
HK1200363A1 (zh) 用於治療癌症的化合物
IL229878A (en) Cancer Treatment Compounds
EP2470534A4 (en) INHIBITION OF JAK BLOCKES TOXICITIES ASSOCIATED WITH INTERFERENCE RNA
EP2205072A4 (en) METHODS OF TREATING DIFFERENT DISEASES AND CONDITIONS, AND COMPOUNDS USED THEREOF
EP1987838A4 (en) NEW CONNECTION TO TUMOR THERAPY
IL213398A0 (en) Compounds for treating cancer
PT2957292T (pt) Terapia de vitiligo
EP2478860A4 (en) HIGH FREQUENCY TREATMENT INSTRUMENT
HK1126182A1 (en) Process for synthesizing sevoflurance
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
EP1986656A4 (en) WITHACNISTINE COMPOUNDS FOR THE TREATMENT OF CANCER
EP2028181A4 (en) PROCESS FOR PRODUCING GLYCIDOL
ZA201000670B (en) Process for producing toluidine compound
EP2250290A4 (en) PTTG1 AS A BIOMARKER FOR CANCER TREATMENT
TWI348916B (en) A novel treatment tool for cancer: rna interference of bcas2
EP2214485A4 (en) METHOD FOR THE TREATMENT OF CANCER
GB0914322D0 (en) Compounds for treating cancer
GB0901794D0 (en) Compounds for treating muscular dystrophy
AU2008903467A0 (en) A method of treatment
AU2008903444A0 (en) A method of treatment
AU2008902088A0 (en) A method of treatment
IL193470A0 (en) Process for preparing of 2-alkyl-3-aryl-prop-2- ene-1-ols

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees